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D-Phenylglycine-L-Dopa (D-PhG-L-Dopa), designed as a dipeptide mimetic prodrug of
dopamine, has been proven to have 31-fold higher oral bioavailability than L-Dopa in rats.
To further investigate if this dipeptide enters the brain, a single-dose pharmacokinetic
study by i.v. administration, in comparison with L-Dopa, was conducted to monitor brain
availability. The dopamine level in the brain was also determined. The results indicated
that both D-PhG-L-Dopa and L-Dopa entered the brain rapidly (Tmax 1 minute) with similar
degrees of penetration (AUCbrain/AUCplasma 8.83% vs. 7.61%). As D-PhG-L-Dopa had higher
systemic exposure than L-Dopa (AUCplasma 23.79 mmol*min/mL vs. 12.09 mmol*min/mL), it
thus had higher brain availability (AUCbrain 2.0 mmol*min/mL vs. 0.92 mmol*min/mL).
Although the AUCbrain dopamine after D-PhG-L-Dopa treatment was only 24% of that from L-
Dopa treatment, it however exhibited higher anti-Parkinsonism activity than L-Dopa
(reduction in rotation number 47.9  5.5% vs. 27.3  4.8%). Higher brain dopamine residual
properties of D-PhG-L-Dopa treatment compared to L-Dopa treatment, namely 3.2 times
longer MRTbrain dopamine (172.15 vs. 53.78 minutes), 10 times longer Tmax brain dopamine (30 vs.
3 minutes) and 8.36 times longer half-life (T1=2 Tmax to end ðminÞ 112.51 vs. 13.46 minutes),
may explain the result. Moreover, the long terminal half-life of brain dopamine upon
D-PhG-L-Dopa treatment indicated its slow dopamine-releasing property compared with
L-Dopa treatment (112.51 vs. 44.85 minutes). It is also important to note that brain dopa-
mine level was better controlled in the D-PhG-L-Dopa group than in the L-Dopa group (Cmax/
Cmin 1.62 vs. 9.85). In conclusion, this study demonstrated that D-PhG-L-Dopa is an intrinsic
dopamine-sustained-releasing prodrug. The limited concentration fluctuation of released
dopamine in the brain is beneficial for the clinical management of Parkinson’s disease.
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Fig. 1 e Structures of dopamine, L-Dopa and D-Phenylglycine-L-Dopa.
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bioavailability of L-Dopa is thus to prevent the drug from
competing with amino acids for absorption via intestinal
amino acid transporters [15].
We reported the discovery of D-Phenylglycine-L-Dopa
(D-PhG-L-Dopa; Fig. 1) using D-Phenylglycine as a delivery tool
for guiding L-Dopa to transport via intestinal oligopeptide
transporter (PepT1). The dipeptide showed an oral absorption
that was 32-fold higher than that of L-Dopa. The higher anti-
Parkinsonism activity of this dipeptide compared to that of
L-Dopamight come from its improved systemic bioavailability
after oral administration [16].
To investigate if D-PhG-L-Dopa enters the brain, pharma-
cokinetic studies for determining the systemic and CNS
bioavailability of this dipeptide, compared with L-Dopa, were
conducted in rats. Brain availability of dopamine upon i.v.
administration of D-PhG-L-Dopa and L-Dopa were determined.
Pharmacokinetic properties of both prodrugs and in vivo anti-
Parkinsonism activity were also analyzed.2. Methods
2.1. Materials
D-PhG-L-Dopa was synthesized in our laboratory [16].
Analytical grade chemicals for biological studies were from
Sigma-Aldrich (St. Louis, MO, USA), E. Merck KG (Darmstadt,
Germany), Fluka Chemika (Buchs, Switzerland), Acros (Morris
Plains, NJ, USA) and Wako (Richmond, VA, USA). Acid-
washed alumina was purchased from RiedaL-de Haen Com-
pany (Spring Valley, CA, USA). High-performance liquid
chromatography (HPLC) grade acetonitrile and methanol
were purchased from Alpus Pharmaceutical Industries Co.
(Gifu, Japan). Branson Sonifier 450 sonicator (Danbury, CT,
USA), Kubota 2010 (Tokyo, Japan), Eppendorf AG 5415C
centrifuge (Hamburg, Germany), Model 905 incubator and
Ystral Laboratory series 10/20 homogenizer (Ballrechten-
Dottingen, Germany) were used in the preparation of bio-
logical samples.
Male Wistar rats (200e250 g) for pharmacokinetic studies
and rotational behavior studies were purchased from the
Laboratory Animal Center of National Taiwan University
(Taipei, Taiwan). The animals were pathogen-free and
allowed to acclimate to the environmentally-controlled
quarters (24  1 C and 12:12 hour lightedark cycle) for at
least 5 days before the experiments. The animal studies were
conducted in accordance with the National Institute of Health
Guide for the Care and Use of Laboratory Animals.2.2. Pharmacokinetic studies
2.2.1. Animal experiments
Male Wistar rats (200e250 g) were fasted for at least 18 hours
prior to the study. The rats were put under a heating lamp to
maintain their body temperatures at 37 C throughout the
experiment. A single dose of D-PhG-L-Dopa (100 mg/kg equiv-
alent to 0.3 mmol/kg) or L-Dopa (59.74 mg/kg equivalent to
0.3 mmol/kg) was dissolved in 2.5 mL of normal saline and
administered i.v. into the tail vein. Blood samples were with-
drawn from the carotid artery at time intervals of 1, 3, 5, 10, 15,
30, 45, 60 and 90minutes before the rats were sacrificed for the
determination of systemic bioavailability. The whole brain
was harvested for the determination of CNS bioavailability. All
procedures involving the use of animals were in compliance
with the guidelines for the use of experimental animals and
approved by the Institutional Animal Care and Use Committee
of Taipei Medical University.
2.2.2. Analytical sample preparation
Heparin sodium (25 IU/mL in 0.3mL of saline) was added to the
blood samples and centrifuged (5585g) at 4 C for 8 minutes.
The plasma was frozen immediately and kept at e78 C until
theywere analyzed,whereupon200mL of theplasmasample in
a 10-mL test tube wasmixedwith 500 mL of 1 M Tris-HCl buffer
(adjusted to pH 8.6 by adding disodium EDTA), 10 mL of dihy-
droxybenzylamine (DHBA, 2 mg/mL, as internal standard) and
100mgof alumina.The tubewas shaken for 15 secondsand the
supernatant was decanted. The alumina was washed four
times with 5 mL of water. The compounds adsorbed on the
alumina were eluted with 200 mL of acid buffer comprising
0.9 mL of glacial acetic acid in 4 mL of 1.0 M phosphate buffer;
30 mL of the solution was then analyzed with HPLC. The iso-
lated brain was immersed in Ringer’s solution, cleaned and
homogenized. After centrifugation (at 5585g and 4 C for 8
minutes), the clear supernatant from the brain homogenate
was subjected to alumina extractionusing the sameprocedure
as that used for preparing the plasma sample.
2.2.3. Chromatography
2.2.3.1. Assay methods. Assays were performed using a HPLC
system with an ion exchange column coupled with an elec-
trochemical detector. The HPLC system consisted of an auto-
sampler (AS950, Jasco, Tokyo, Japan), a Waters Model 600E
solvent delivery pump (Millipore, Milford, MA, USA), a Model
LC-4C electrochemical detector with a glassy-carbon electrode
(Bioanalytical Systems, Inc., West Lafayette, IN, USA), and an
integrator (Macintosh LC II with Macintegrator I). A Nucleosil
10 SA cationic ion-exchange column (10 mm, 300  4.0 mm;
Macherey-Nagel, Du¨ren, Germany) with a mobile phase
Fig. 2 e Chromatogram of D-PhG-L-Dopa, L-Dopa, internal
standard dihydroxybenzylamine (DHBA) and dopamine in
brain sample.
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phosphate buffer (pH 2.0) at a flow rate of 2.0mL/minwas used
for the analysis of D-PhG-L-Dopa and L-Dopa. A C18 reversed
phase microbore column (particle size 5 mm, 150  1 mm I.D.;
Bioanalytical Systems, West Lafayette, IN, USA) was used for
the analysis of dopamine in brain homogenate. The eluents
were filtered through a Millipore 0.22-mm filter and degassed
prior to analysis. The flow rate was set at 0.05 mL/min.
2.2.3.2. Validation of assay methods. The lower limit of
detection (LOD) and limit of quantification (LOQ) of D-PhG-L-
Dopa and L-Dopa were determined. Assay methods were
validated by determining the precision and accuracy of intra-
day and inter-day analyses of serum standards over a period
of 6 days. The coefficients of variation for inter- and intra-day
assays were less than 18%.
2.2.3.3. Data treatment. Pharmacokinetic parameters (Cmax,
Tmax, AUC, AUMC, elimination rate constant, Vdss, T1/2) were
calculated using the logelinear trapezoidal rule. Plasma con-
centrations after i.v. administration of drugs were calculated
using WINNONLIN software by non-compartment model.
Data analyses were performed on Microsoft Excel and repre-
sented as mean  SD for n experiments. Treatment differ-
ences were evaluated by paired t-test.
2.2.4. Rotational behavior of rats [17e20]
Male Wistar rats (180e200 g) were anesthetized with pento-
barbital sodium (30mg/kg bodyweight, i.p.) and theheadswere
fixed in a David-Kopf steric taxic frame. A solution of 6-
hydroxydopamine (6-OHDA, 2.0 mg/mL  8 mL) in saline was
infused using Paxinos andWatson coordinates (AP 5.3, L 2.0, H
7.8mm[17]) into theunilateral substantianigra compacta (SNc)
of the brain with a syringe pump through a 30-gauge stainless
steel needle at a flow rate of 2 mL/min. After 2 weeks’ recovery
period, the 6-OHDAtreated ratswere placed in a spherical bowl
(radius 20 cm) and secured by a thoracic harness which was
connected to a 486 PC computer for automatic recording of
rotation induced by (þ)-methamphetamine (MA; from Sigma-
Aldrich, St. Louis, MO, USA). The rotational behavior of rats
was recorded 10 minutes after MA treatment (MA in saline,
4 mg/kg body weight of rat, s.c.). The number of turns recorded
wasdefined as thecontrol value (T0) for each individual animal.
Only animals showing a T0 greater than 400 were chosen for
further experiments. After 2 weeks’ wash-out period, the ani-
mals were subjected to drug treatment. A single dose
(0.051mmol/kg) of each test compoundwasadministered i.p. to
rats 5 minutes prior to MA treatment (4.0 mg/kg body weight,
s.c.). The rotation counted for a period of 110 minutes starting
10 minutes after MA treatment was recorded as Td for each
tested rat. The percentage of reduction in rotation for each
animal was calculated and presented as (Td  T0)/T0  100%.Fig. 3 e The concentration-time curves of D-PhG-L-Dopa in
rat blood and brain after i.v. administration (50 mg/kg). The
values represent the group mean ± SD (n [ 4).3. Results
3.1. Chromatography and validation of assay methods
The HPLC chromatogram for the analysis of D-PhG-L-Dopa,
L-Dopa and dopamine is depicted in Fig. 2. The LODs ofD-PhG-L-Dopa in plasma samples and brain homogenates
were 0.1 mg/mL and 0.25 mg/mL, respectively. The LOQswere in
the range of 0.5 mg/mL and 12.5 mg/mL for plasma samples
(R2 ¼ 0.9999 intra-day; R2 ¼ 0.9947 inter-day) and brain ho-
mogenates (R2 ¼ 0.9973 intra-day; R2 ¼ 0.9999 inter-day),
respectively. The LOD of L-Dopa was 0.05 mg/mL in plasma
samples and brain homogenates. LOQ was in the range of
0.05 m/mL for plasma samples (R2 ¼ 0.9994 intra-day;
R2 ¼ 0.9999 inter-day) and 2.5 mg/mL for brain homogenates
(R2 ¼ 0.9996 intra-day; R2 ¼ 0.9987 inter-day). The LOQ values
of dopamine for brain homogenates were in the range of
0.05 mg/mL and 1.25 mg/mL (R2 ¼ 0.9950 intra-day; R2 ¼ 0.9990
inter-day), respectively. The coefficients of variation of all
assays were less than 18%.3.2. Systemic and brain concentrationetime profile upon
i.v. administration of D-PhG-L-Dopa
The plasma and brain concentrationetime profile of D-PhG-L-
Dopa after i.v. administration (50 mg/kg) is depicted in Fig. 3.
Fig. 4 e Concentrationetime curve of (A) plasma and (B) brain homogenate after i.v. administration of D-PhG-L-Dopa (n[ 6)
or L-Dopa (n [ 4) in rats.
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and L-Dopa
Equal molar (0.3 mmol/kg) of D-PhG-L-Dopa or L-Dopa was
administered to the rats by i.v. injection. For comparison, the
concentrationetime curves in plasma (Fig. 4A) and in brain
homogenate (Fig. 4B) are depicted. The dopamine profile in
brain homogenate upon administration of D-PhG-L-Dopa or L-
Dopa is depicted in Fig. 5.
The pharmacokinetic parameters of D-PhG-L-Dopa and L-
Dopa are summarized in Table 1. AUCbrain/AUCplasma was
calculated as an indicator of the portion of prodrugs that
penetrated into the brain. As time factor is important for the
biotransformation of the prodrugs to parent dopamine,
AUMCbrain/AUMCplasma of the prodrugs was also calculated for
comparison.
The key pharmacokinetic parameters of dopamine in brain
upon i.v. administration of D-PhG-L-Dopa and L-Dopa are
summarized in Table 2. The CNS bioavailability of dopamine
released from both prodrugs was compared. MRTbrain dopamine,
T1/2 and Tmax are also listed for the comparison of dopamine-
releasing properties.Table 1 e Comparison of pharmacokinetic parameters of
D-PhG-L-Dopa and L-Dopa.
D-PhG-L-Dopa L-Dopa Ratio3.4. Anti-Parkinsonism effect in rats
The in vivo anti-Parkinsonism effect was determined, in
crossover design experiments, with a conventional rotationFig. 5 e Brain dopamine after i.v. administration of D-PhG-L-
Dopa (n [ 6) or L-Dopa (n [ 4).model measured in 6-OHDA-treated unilateral striatal-
lesioned rats in which rotations were elicited with (þ)-MA.
The reduction in rotational counts was used as an indicator of
Parkinsonism activity. Both D-PhG-L-Dopa and L-Dopa
demonstrated inhibition of MA-induced rotation of rats. With
equalmolars of test compound administered, the activity of D-
PhG-L-Dopa in reducing the rotation of rats was significantly
higher than that of L-Dopa ( p < 0.05, Table 3).4. Discussion
This study aimed to compare the comparative systemic and
brain bioavailability of D-PhG-L-Dopa and L-Dopa, the degree of
their penetration through the bloodebrain barrier, and dopa-
mine in the brain. Systemic exposures upon i.v. injection of
the prodrugs were investigated first. D-PhG-L-Dopa demon-
strated 1.97-fold higher systemic bioavailability than L-Dopa
(AUCplasma 23.79 mmol*min/mL vs. 12.09 mmol*min/mL), prob-
ably due to its lower clearance rate and larger volume of dis-
tribution. The biological half-life of this dipeptide was longer(I)
(n ¼ 6)
(II)
(n ¼ 4)
(I/II)
AUCbrain (mmol*min/mL) (a) 2.10 0.92 2.28
AUCplasma (mmol*min/mL) (b) 23.79 12.09 1.97
AUCbrain/AUCplasma (a/b) 8.83% 7.61% 1.16
AUMCbrain (mmol*min
2/mL) (c) 85.22 38.06 2.26
AUMCplasma (mmol*min
2/mL) (d) 454.72 190.21 2.39
AUMCbrain/AUMCplasma (c/d) 18.74% 20.01% 0.94
Tmax, brain (min) 1.0 1.0 d
Cmax, plasma (mmol/mL) 3.34 1.88 1.78
Cmax, brain (mmol/mL) 0.12 0.02 5.90
T1/2, plasma (min) 13.25 10.90 1.22
MRTplasma (min) 19.11 15.73 1.21
CLp, plasma (L/kg/min) 0.013 0.042 0.31
Vdssplasma (L/kg) 0.243 0.066 3.68
AUCbrain/AUCplasma (a/b) ¼ the fraction of prodrug that penetrated
into the brain.
Table 2e Pharmacokinetic parameters of brain dopamine
after i.v. administration of D-PhG-L-Dopa and L-Dopa.
From D-PhG-
L-Dopa
(n ¼ 6) (I)
From
L-Dopa
(n ¼ 4) (II)
Ratio
(I/II)
AUCbrain dopamine (mmol*min/mL) 0.42 1.75 0.24
AUMCbrain dopamine
(mmol*min2/mL)
32.77 64.28 0.51
MRT (min) 172.15 53.78 3.20
Cmax (mmol/mL) 2.32 60.58 0.38
Cmin (mmol/mL) 1.43 6.15 0.23
Cmax/Cmin 1.62 9.85 0.16
Tmax (min) 30.0 3.0 10.0
T1=2 Tmax to end ðminÞ 112.51 13.46 8.36
T1/2, 30 min to end (min) 112.51 44.85 2.51
Fig. 6 e Proposed biological transformation of D-PhG-L-
Dopa and L-Dopa prodrugs to dopamine.
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consequence, the AUMCplasma of the D-PhG-L-Dopa dipeptide
was 2.39 times higher than that of L-Dopa (454.72 mmol*min2/
mL vs. 190.21 mmol*min2/mL) (Table 1).
Both D-PhG-L-Dopa and L-Dopa penetrated to the brain
rapidly (Tmax brain 1minute). TheAUCbrain of D-PhG-L-Dopawas
2.28-fold larger than that of L-Dopa (2.10 mmol*min/mL vs.
0.92 mmol*min/mL). The Cmax-brain of D-PhG-L-Dopa was 5.90-
fold higher than that of L-Dopa (0.12 mmol/mL vs. 0.02 mmol/
mL). As the fractions of systemic D-PhG-L-Dopa and L-Dopa
that penetrated to the brain (AUCbrain/AUCplasma) were similar
(8.83% vs. 7.61%), the higher AUCbrain and Cmax-brain of D-PhG-L-
Dopa compared to that of L-Dopa might come from its higher
systemic exposure (Table 1).
As brain dopamine exposures were compared,
AUCbrain-dopamine released from D-PhG-L-Dopa was only 24%
of that released from L-Dopa (0.42 mmol*min/mL vs.
1.75 mmol*min/mL) (Table 2). However, themean residual time
(MRTbrain dopamine) of the dipeptide was 3.20 times longer than
that of L-Dopa (172.15 minutes vs. 53.78 minutes). It also
exhibited a 10 times longer Tmax brain dopamine (30.0 minutes vs.
3.0 minutes) and 8.36 times longer T1=2 Tmax to end (112.51 mi-
nutes vs. 13.46 minutes) than L-Dopa. The terminal half-life
(T1/2 30 min to end) of brain dopamine upon D-PhG-L-Dopa
administration was 2.51 times longer than that upon L-Dopa
administration (112.51 minutes vs. 44.85 minutes). This
supported our design of this dipeptide as a dopamine prodrug
for preventing or prolonging the fast decarboxylationTable 3 e Equal molars of D-PhG-L-Dopa and L-Dopa were
administered i.p. and anti-Parkinsonism activities were
determined by rotational behavior assay in crossover
experiments.
Compound Dose
(mg/kg)a
No. of
experiments
Reduction
in rotation
(%, mean  SD)
Paired
t-test
D-PhG-L-Dopa 16.7 10 47.9  5.5 p < 0.05
L-Dopa 10.0 8 27.3  4.8 Control
a The dose used in the experiments was 0.051 mmol/kg for each
compound.commonly encountered with L-Dopa administration (Fig. 6).
The pharmacokinetic profile of brain dopamine also
confirmed the finding from our previous study that oral
administration of D-PhG-L-Dopa led to an intrinsic sustained
dopamine-releasing profile in rats [16].
Although brain dopamine exposure (AUCbrain dopamine) on
i.v. administration of D-PhG-L-Dopawas less thanwith L-Dopa,
this dipeptide demonstrated higher activity in reducing the
rotation of Parkinsonism rats (47.9  5.5% vs. 27.3  4.8%,
p < 0.001, i.p.). The sustained dopamine-releasing might
explain its effective anti-Parkinsonism activity. Reports have
indicated that pulsatile administration of dopamine agonist
induced dopamine-related dyskinesia, and repeated admin-
istration will result in wearing-off phenomenon which is
generally observed in chronic Parkinsonism patients
[13,21,22]. Long-term use of L-Dopa may lead to a decreased
therapeutic window for individual patients; therefore, moni-
toring of blood L-Dopa level is important in the clinical man-
agement of Parkinson’s disease. Various approaches including
new formulation and new molecular entity design were thus
undertaken to achieve sustained-dopamine releasing prop-
erties which maintained a stable concentration profile of
dopamine [15,23]. In our case, although brain dopamine (Cmax
brain dopamine) on D-PhG-L-Dopa administration was much
lower than from L-Dopa administration (2.32 nmol/mL vs.
60.58 nmol/mL), the concentration range (Cmax brain dopamine/
Cmin brain dopamine) was six times narrower (1.62 vs. 9.85), which
greatly reduced the risk from fluctuations in concentration.5. Conclusion
The CNS bioavailability of D-PhG-L-Dopa and L-Dopa, and the
brain dopamine level after i.v. injection of both compounds
were investigated. D-PhG-L-Dopa exhibited lower CNS dopa-
mine exposure than L-Dopa. However, it exhibited an intrinsic
sustained dopamine-releasing profile with longer CNS dopa-
mine residual properties and more stable dopamine concen-
tration profile. The sustained dopamine-releasing property of
D-PhG-L-Dopa might be beneficial for clinical management,
indicating its usefulness as a potential agent for treating
Parkinson’s disease.
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